Scarica l'app Stockscreener
0.5652
5.48%
-0.0328
Dopo l'orario di chiusura:
.62
0.0548
+9.70%
Precedente Chiudi:
$0.598
Aprire:
$0.6
Volume 24 ore:
234.38K
Relative Volume:
0.22
Capitalizzazione di mercato:
$18.81M
Reddito:
-
Utile/perdita netta:
$-55.73M
Rapporto P/E:
-0.1751
EPS:
-3.2274
Flusso di cassa netto:
$-68.87M
1 W Prestazione:
-7.21%
1M Prestazione:
-19.82%
6M Prestazione:
-17.85%
1 anno Prestazione:
-76.64%
Intervallo 1D:
$0.5625
$0.615
Intervallo di 1 settimana:
$0.5625
$0.6753
Portata 52W:
$0.3151
$2.69
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Nome
Jasper Therapeutics Inc
Settore
Industria
Telefono
(650) 549-1400
Indirizzo
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
0.5652 | 20.27M | 0 | -55.73M | -68.87M | -3.2274 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-23 | Ripresa | UBS | Neutral |
| 2026-01-13 | Iniziato | Rodman & Renshaw | Buy |
| 2025-07-08 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | Iniziato | UBS | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-09-09 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-08 | Iniziato | BTIG Research | Buy |
| 2024-06-27 | Iniziato | Stifel | Buy |
| 2024-05-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-03 | Iniziato | Evercore ISI | Outperform |
| 2024-03-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-03-18 | Iniziato | TD Cowen | Outperform |
| 2023-08-11 | Iniziato | CapitalOne | Overweight |
| 2022-02-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Iniziato | Credit Suisse | Outperform |
| 2021-10-21 | Iniziato | William Blair | Outperform |
| 2021-10-20 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-13 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie
Form 8K Jasper Therapeutics Inc For: 1 October - Investing.com India
Jasper Therapeutics stock names interim finance leaders after CFO exit - AD HOC NEWS
Jasper Therapeutics announces CFO resignation and interim appointments - Investing.com
Form 8K Jasper Therapeutics Inc For: 28 September By Investing.com - Investing.com Nigeria
Herb Cross to Resign as Jasper Therapeutics CFO; Jeet Mahal, Rick Ruiz and Matthew Ros Appointed to Interim Roles - TradingView
Three interim appointments will follow the finance chief's departure at Jasper Therapeutics (JSPR). - Stock Titan
Jasper Therapeutics stock gains 4.05 percent as vote nears - AD HOC NEWS
Ten Jasper Therapeutics (JSPR) warrants are exercisable for one share as Nasdaq moves to remove their listing. - Stock Titan
Jasper Therapeutics stock gains 1.39 percent on Nasdaq - AD HOC NEWS
Jasper Therapeutics stock holds at USD 5.42 as pipeline data guide trading - AD HOC NEWS
Jasper Therapeutics stock holds recent gains as investors watch latest trial and funding data - AD HOC NEWS
Jasper Therapeutics Inc (JSPRW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Jasper Therapeutics, Inc.(NasdaqCM: JSPR) added to NASDAQ Composite Index - marketscreener.com
JSPR: Merger yields robust pipeline and funding, with major clinical and regulatory milestones ahead - TradingView
Jasper Therapeutics at H.C. Wainwright: cash and catalysts By Investing.com - Investing.com Canada
JSPR: Merger creates a robust immunology pipeline with major clinical and regulatory milestones ahead - TradingView
Jasper Therapeutics appoints two executives to key roles By Investing.com - Investing.com Australia
Jasper Therapeutics appoints two executives to key roles - Investing.com
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments - Yahoo Finance
A biotech company's New York talk will be webcast live - Stock Titan
Jasper Therapeutics (NASDAQ: JSPR) Schedules September 30 Vote on Increasing Authorized Common Stock - kalkinemedia.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Jasper Therapeutics Inc (JSPRW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Jasper Therapeutics Inc (JSPRW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Jasper Therapeutics (NASDAQ: JSPR) on clock after Nasdaq equity warning - Stock Titan
Jasper (JSPR) Latest: Gains 3.59% to Reach $0.72 in Latest Trading; Price Levels: Price Remains Between $0.68 Support and $0.76 Resistance under the Current SnapshotLong Setup Ideas - vinanet.vn
Wenru Song Net Worth (2026) - GuruFocus
Kira Pharmaceuticals - The Pharma Letter
Jasper Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Velan group shifts to passive stake in Jasper (NASDAQ: JSPR) - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Jasper Therapeutics beats Q2 expectations but shares fall after results - Yahoo Finance
Jasper Therapeutics beats earnings expectations but stock falls 4% By Investing.com - Investing.com South Africa
Jasper Therapeutics beats earnings expectations but stock falls 4% - Investing.com
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com
JSPR Q1 2026 Earnings: 91.94% EPS Beat Signals Cost Discipline, But Stock Slips 8.46%Earnings Season Preview - vinanet.vn
Jasper Therapeutics Q2 EPS of $(0.10) beats estimates - scanx.trade
Jasper Therapeutics (JSPR) narrows Q2 2026 loss, closes Kira deal and $132M PIPE - Stock Titan
Jasper Therapeutics Reports $2.8 Million Second-Quarter Net Loss - Quiver Quantitative
Jasper Therapeutics, Inc. (JSPR) stock: Climbs on Kira Merger and $132M Raise as Pipeline Consolidates - Blockonomi
Jasper Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln - TradingView
Jasper Therapeutics, Inc. 2Q 2026: Net loss $(2.8M), EPS $(0.10) — 10-Q Summary - TradingView
Jasper Therapeutics Reports Q2 2026 Results and Completion of Kira Pharmaceuticals Acquisition - Quiver Quantitative
JSPR Financials: Income Statement, Balance Sheet & Cash Flow | Jasper Therapeutics Inc - Stock Titan
Jasper Therapeutics (JSPR) slashes losses, acquires Kira and raises $132M - Stock Titan
Piper Sandler Initiates Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $2 - Moomoo
Piper Sandler initiates Jasper Therapeutics stock at overweight By Investing.com - Investing.com Canada
Piper Sandler Initiates Jasper Therapeutics With Overweight Rating, $2 Price Target - Yahoo Finance
$Jasper Therapeutics (JSPR.US)$ Goodbye - Moomoo
JSPR DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC - The National Law Review
Jasper Therapeutics Inc Azioni (JSPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):